antirheumatic agents

Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al
Jixin Zhong, Lingli Dong

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218441; DOI: 10.1136/annrheumdis-2020-218441
Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al
Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218432; DOI: 10.1136/annrheumdis-2020-218432
Response to: ‘COVID-19 in patients with rheumatic diseases: what is the real mortality risk?’ by Marques et al
Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218431; DOI: 10.1136/annrheumdis-2020-218431
Should patients starting biologics be screened for COVID-19?
Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado

Annals of the Rheumatic Diseases Jul 2020, annrheumdis-2020-218437; DOI: 10.1136/annrheumdis-2020-218437
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
Robert BM Landewé, Pedro M Machado, Féline Kroon, Hans WJ Bijlsma, Gerd R Burmester, Loreto Carmona, Bernard Combe, Massimo Galli, Laure Gossec, Annamaria Iagnocco, John D Isaacs, Xavier Mariette, Iain McInnes, Ulf Mueller-Ladner, Peter Openshaw, Josef S Smolen, Tanja A Stamm, Dieter Wiek, Hendrik Schulze-Koops

Annals of the Rheumatic Diseases Jul 2020, 79 (7) 851-858; DOI: 10.1136/annrheumdis-2020-217877
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist
Elizabeth R Graef, Jean W Liew, Michael S Putman, Julia F Simard, Emily Sirotich, Francis Berenbaum, Alí Duarte-García, Rebecca Grainger, Carly Harrison, Maximilian F Konig, Peter Korsten, Laurie Proulx, Dawn P Richards, Philip C Robinson, Sebastian E Sattui, Manuel Francisco Ugarte-Gil, Kristen J Young, Alfred HJ Kim, Jeffrey A Sparks

Annals of the Rheumatic Diseases Jun 2020, 79 (6) 734-736; DOI: 10.1136/annrheumdis-2020-217480
Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19
Chenyang Lu, Shasha Li, Yi Liu

Annals of the Rheumatic Diseases Jun 2020, 79 (6) 737-739; DOI: 10.1136/annrheumdis-2020-217460
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: ‘Does hydroxychloroquine prevent the transmission of COVID-19?’ by Heldwein and Calado and ‘SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment’ by Joob and Wiwanitkit
Sara Monti, Carlomaurizio Montecucco

Annals of the Rheumatic Diseases Jun 2020, 79 (6) e62; DOI: 10.1136/annrheumdis-2020-217524
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli, Carlomaurizio Montecucco

Annals of the Rheumatic Diseases May 2020, 79 (5) 667-668; DOI: 10.1136/annrheumdis-2020-217424
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
Gerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, Indalecio Monteagudo-Sáez, Michel Malaise, Athanasios G Tzioufas, Johannes W J Bijlsma, Kristina Unnebrink, Sonja Kary, Hartmut Kupper

Annals of the Rheumatic Diseases Jun 2007, 66 (6) 732-739; DOI: 10.1136/ard.2006.066761

Main menu

antirheumatic agents

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

antirheumatic agents

Pages